National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/8664

Target Organs and Levels of Evidence for TR-443

Toxicology and Carcinogenesis Studies of Oxazepam (CASRN 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
Oxazepam
604-75-1
12/01/1992Tranquilizer -- used therapeutically as a sedative-hypnotic and antianxiety agent.Dosed-Feed
SW: 0, 2500, OR 5000; B6: 0, 125, 2500, OR 5000 PPM; 60/GROUP
Battelle Columbus Laboratory

Levels of Evidence

Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: (SWISS-WEBSTER) ADENOMA 1/60 35/60 50/60; CARCINOMA 0/60 5/60 19/60; (B6C3F1) ADENOMA 17/49 18/50 34/50 32/50; CARCINOMA 9/49 5/50 45/50 50/50; HEPATOBLASTOMA 0/49 2/50 21/50 13/50
Non-Neoplastic Lesions
  • LIVER: (SWISS-WEBSTER & B6C3F1) CENTRILOBULAR HYPERTROPHY
  • VARIOUS ORGANS: (SWISS-WEBSTER) INCREASED INCIDENCE AND SEVERITY OF SYSTEMIC AMYLOID DEPOSITION
  • THYROID GLAND: (B6C3F1) FOLLICULAR CELL HYPERPLASIA
  • TESTIS: (B6C3F1) ATROPHY; EPIDIDYMAL INFILTRATES
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: (SWISS-WEBSTER) ADENOMA 0/60 22/59 47/59; CARCINOMA 1/60 1/59 11/59; (B6C3F1) ADENOMA 25/50 35/50 35/50 36/50; CARCINOMA 9/50 5/50 49/50 44/50; HEPATOBLASTOMA 0/50 1/50 8/50 8/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 4/50 5/50 6/50
Non-Neoplastic Lesions
  • LIVER: (SWISS-WEBSTER & B6C3F1) CENTRILOBULAR HYPERTROPHY
  • VARIOUS ORGANS: (SWISS-WEBSTER) INCREASED INCIDENCE AND SEVERITY OF SYSTEMIC AMYLOID DEPOSITION
  • THYROID GLAND: (B6C3F1) FOLLICULAR CELL HYPERPLASIA


NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.